바이오정보모아 (BioJungboMoa) — ADC · Antibody

8428프로그램 40FDA 승인

69오늘 방문

5,832누적 방문

7303갱신 대기 S–CData Tier S/A/B차세대 →Insight 1032HER2 breast 4683Antibody 2713CGT →Psoriasis →NSCLC 40FDA 승인

피드 Data Tier 차세대 Insight

anti-MESO CAR-T cells (anti-MESO CAR-T cells)

Ovarian Cancer · Ovarian Cancer

#OvarianCancer#CGT#Phase1#세포유전치료#CAR-T+2

임상시험 12상태 ACTIVE

CGTBiologicstaleiCell Gene TherapeuticsPhase 1

Anti-CD33 CAR T-cells (Anti-CD33 CAR T-cells)

Acute Myeloid Leukemia; Recurrent Adult Acute Myeloid Leukemia · CD33

#CD33#CGT#Phase1#세포유전치료#CAR-T+4

임상시험 12상태 RECRUITING

AntibodystaleBeiGenePhase 2

disitamab vedotin (Disitamab Vedotin, RC48, RC48 Combined With Tislelizumab)

Upper Tract Urothelial Carcinoma · PD-1

#PD-1#Antibody#Phase2#항체#면역항체+3

임상시험 12상태 RECRUITING

AntibodystaleJanssenPhase 1

Topical infliximab (Topical infliximab)

Sterile Corneal Melt · Glaucoma Following Surgery

#GlaucomaFollowingSurgery#Antibody#Phase1#항체#면역항체+3

임상시험 11상태 ACTIVE

ADCBiologicstaleNovartis PharmaceuticalsPhase 2

CDK4/6 inhibitor+AI or fulvestrant (CDK4/6 inhibitor+AI or fulvestrant)

Salivary Gland Carcinoma; Precision Therapy · Salivary Gland Carcinoma

#SalivaryGlandCarcinoma#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+2

효능 ORR 19.3%임상시험 11상태 RECRUITING

ADCBiologicstaleLepu Biopharma Co., Ltd.Phase 2

Becotatug Vedotin and Pucotenlimab (Becotatug Vedotin and Pucotenlimab)

Hypopharyngeal Squamous Cell Carcinoma · Nasopharyngeal Cancinoma (NPC)

#NasopharyngealCancinomaNPC#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+2

임상시험 11상태 RECRUITING

AntibodystaleLepu Medical Technology (Beijin…Phase 2

MRG003+Pucotenlimab (MRG003+Pucotenlimab)

Locally Advanced Oral and Oropharyngeal Squamous Cell Carcinoma · Locally Advanced Oral and Oropharyngeal

#LocallyAdvancedOralandOropharyng#Antibody#Phase2#항체#면역항체+2

임상시험 11상태 RECRUITING

CGTBiologicstaleKyverna TherapeuticsPhase 2

KYV-101 anti-CD19 CAR-T cell therapy (KYV-101 anti-CD19 CAR-T cell therapy)

Lupus Nephritis; Lupus Nephritis - World Health Organization (WHO) Class III · CD19

#CD19#CGT#Phase2#세포유전치료#CAR-T+5

임상시험 11상태 RECRUITING

ADCBiologicstalePfizerPhase 2

PF-08634404 (PF-08634404)

Urothelial Cancer; Advanced/Metastatic Urothelial Cancer · Urothelial Cancer

#UrothelialCancer#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+3

임상시험 11상태 RECRUITING

ADCBiologicstaleSWOG Cancer Research NetworkPhase 2

ABBV-399 (ABBV-399)

Recurrent Squamous Cell Lung Carcinoma; Stage IV Squamous Cell Lung Carcinoma AJCC V7 · Recurrent Squamous Cell Lung Carcinoma

#RecurrentSquamousCellLungCarcino#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+2

효능 ORR 33.3%임상시험 11상태 ACTIVE

CGTBiologicstaleTaiho Oncology, Inc.Phase 2

ASTX660 (ASTX660)

Solid Tumors; Lymphoma · Solid Tumors

#SolidTumors#CGT#Phase2#세포유전치료#CAR-T+4

임상시험 11상태 RECRUITING

AntibodystaleNeovii BiotechPhase 2

Transplant Conditioning with Mobilization and Alemtuzumab (Transplant Conditioning with Mobilization and Alemtuzumab)

Severe Combined Immunodeficiency · Severe Combined Immunodeficiency

#SevereCombinedImmunodeficiency#Antibody#Phase2#항체#면역항체+2

임상시험 11상태 DISCONTINUED

AntibodystaleShi MingPhase 2

Candonilimab (Candonilimab)

Hepatocellular Carcinoma · Hepatocellular Carcinoma

#HepatocellularCarcinoma#Antibody#Phase2#항체#면역항체+2

임상시험 11상태 DISCONTINUED

ADCBiologicstaleAstraZenecaPhase 2

durvalumab (Imfinzi, Datopotamab deruxtecan + Durvalumab)

Breast Neoplasms; Breast Cancer · HER2

#HER2#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+3

효능 ORR 56.5%임상시험 11상태 RECRUITING

CGTBiologicstaleCARsgen Therapeutics Co., Ltd.Phase 1

anti-GPC3 CAR-T (anti-GPC3 CAR-T)

Hepatocellular Carcinoma · Advanced Hepatocellular Carcinoma

#AdvancedHepatocellularCarcinoma#CGT#Phase1#세포유전치료#CAR-T+3

임상시험 11상태 ACTIVE

ADCBiologicstaleShanghai JMT-Bio Inc.Phase 3

JSKN003 (JSKN003)

Unrespectable Locally Advanced and or Metastatic HER2 Positive Breast Cancer Participants · HER2

#HER2#ADC#Phase3#항체약물접합체#antibody-drug-conjugate+2

임상시험 11상태 RECRUITING

AntibodystaleAmgenPhase 2

Panitumumab-IRDye800 (Panitumumab-IRDye800)

Pancreatic Adenocarcinoma · Malignant Brain Neoplasm

#MalignantBrainNeoplasm#Antibody#Phase2#항체#면역항체+3

임상시험 11상태 RECRUITING

ADCBiologicstaleRemeGen Co., Ltd.Phase 2

disitamab vedotin (Disitamab Vedotin, RC48, RC48 + Carboplatin)

Ovarian Cancer; HER2 · HER2

#HER2#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+2

임상시험 11상태 RECRUITING

ADCBiologicstaleRochePhase 1

ado-trastuzumab emtansine (Kadcyla, T-DM1, PD-0332991 and T-DM1)

Advanced Breast Cancer · Advanced Breast Cancer

#AdvancedBreastCancer#ADC#Phase1#항체약물접합체#antibody-drug-conjugate+1

임상시험 11상태 ACTIVE

CGTSHOTFDACuratedFDABiologicFerring PharmaceuticalsHuman interferon alfa-2bApproved

nadofaragene firadenovec (Adstiladrin, rAd-IFNα/Syn3, nadofaragene firadenovec-vncg)

High-risk BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) · IFNα2b (adenoviral)

#IFN2badenoviral#CGT#Approved#FDA승인#바이오정보모아추천+5

효능 ORR 55%임상시험 10상태 APPROVED

ADCBiologicstaleHoffmann-La RochePhase 2

89Zr-Df-IAB22M2C (89Zr-Df-IAB22M2C)

Non-Hodgkins Lymphoma · Non-Hodgkins Lymphoma

#Non-HodgkinsLymphoma#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+1

임상시험 10상태 RECRUITING

ADCBiologicstaleMerck Sharp & Dohme LLCPhase 2

Zilovertamab vedotin (Zilovertamab vedotin)

Lymphoma, Large B-Cell, Diffuse · HER2

#HER2#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+4

효능 ORR 1.4%임상시험 10상태 DISCONTINUED

CGTBiologicstaleNational Heart, Lung, and Blood…vedotinPhase 1

AVL (AAV8hAAT, AAV8hAAT(AVL))

Alpha 1-Antitrypsin Deficiency · Alpha 1-Antitrypsin Deficiency

#Alpha1-AntitrypsinDeficiency#CGT#Phase1#세포유전치료#CAR-T+4

임상시험 10상태 RECRUITING

ADCBiologicstaleRemeGenPhase 2

disitamab vedotin (Disitamab Vedotin, RC48, Disitamab Vedotin Combined With Sintilimab)

Gastric Cancer · Gastric Cancer

#GastricCancer#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+1

임상시험 10상태 ACTIVE

CGTBiologicstaleTakedaPhase 2

Anti-CD19 CAR T Cells Preparation (Anti-CD19 CAR T Cells Preparation)

Hematologic Malignancies · CD19

#CD19#CGT#Phase2#세포유전치료#CAR-T+3

효능 ORR 20%임상시험 10상태 RECRUITING

34 / 142 페이지

← 이전 다음 →

전체 8,428개 프로그램 보기

갱신 기록 없음 · 14일 주기 · 방문 69 / 5,832

함께 비교하는 진짜 ADC · Antibody · CGT 데이터

추천 비교

빠른 검색 · 이슈 태그

anti-MESO CAR-T cells (anti-MESO CAR-T cells)

Anti-CD33 CAR T-cells (Anti-CD33 CAR T-cells)

disitamab vedotin (Disitamab Vedotin, RC48, RC48 Combined With Tislelizumab)

Topical infliximab (Topical infliximab)

CDK4/6 inhibitor+AI or fulvestrant (CDK4/6 inhibitor+AI or fulvestrant)

Becotatug Vedotin and Pucotenlimab (Becotatug Vedotin and Pucotenlimab)

MRG003+Pucotenlimab (MRG003+Pucotenlimab)

KYV-101 anti-CD19 CAR-T cell therapy (KYV-101 anti-CD19 CAR-T cell therapy)

PF-08634404 (PF-08634404)

ABBV-399 (ABBV-399)

ASTX660 (ASTX660)

Transplant Conditioning with Mobilization and Alemtuzumab (Transplant Conditioning with Mobilization and Alemtuzumab)

Candonilimab (Candonilimab)

durvalumab (Imfinzi, Datopotamab deruxtecan + Durvalumab)

anti-GPC3 CAR-T (anti-GPC3 CAR-T)

JSKN003 (JSKN003)

Panitumumab-IRDye800 (Panitumumab-IRDye800)

disitamab vedotin (Disitamab Vedotin, RC48, RC48 + Carboplatin)

ado-trastuzumab emtansine (Kadcyla, T-DM1, PD-0332991 and T-DM1)

nadofaragene firadenovec (Adstiladrin, rAd-IFNα/Syn3, nadofaragene firadenovec-vncg)

89Zr-Df-IAB22M2C (89Zr-Df-IAB22M2C)

Zilovertamab vedotin (Zilovertamab vedotin)

AVL (AAV8hAAT, AAV8hAAT(AVL))

disitamab vedotin (Disitamab Vedotin, RC48, Disitamab Vedotin Combined With Sintilimab)

Anti-CD19 CAR T Cells Preparation (Anti-CD19 CAR T Cells Preparation)

함께 비교하는 진짜 ADC · Antibody · CGT 데이터

추천 비교

빠른 검색 · 이슈 태그

실시간 이슈 · 검색

anti-MESO CAR-T cells (anti-MESO CAR-T cells)

Anti-CD33 CAR T-cells (Anti-CD33 CAR T-cells)

disitamab vedotin (Disitamab Vedotin, RC48, RC48 Combined With Tislelizumab)

Topical infliximab (Topical infliximab)

CDK4/6 inhibitor+AI or fulvestrant (CDK4/6 inhibitor+AI or fulvestrant)

Becotatug Vedotin and Pucotenlimab (Becotatug Vedotin and Pucotenlimab)

MRG003+Pucotenlimab (MRG003+Pucotenlimab)

KYV-101 anti-CD19 CAR-T cell therapy (KYV-101 anti-CD19 CAR-T cell therapy)

PF-08634404 (PF-08634404)

ABBV-399 (ABBV-399)

ASTX660 (ASTX660)

Transplant Conditioning with Mobilization and Alemtuzumab (Transplant Conditioning with Mobilization and Alemtuzumab)

Candonilimab (Candonilimab)

durvalumab (Imfinzi, Datopotamab deruxtecan + Durvalumab)

anti-GPC3 CAR-T (anti-GPC3 CAR-T)

JSKN003 (JSKN003)

Panitumumab-IRDye800 (Panitumumab-IRDye800)

disitamab vedotin (Disitamab Vedotin, RC48, RC48 + Carboplatin)

ado-trastuzumab emtansine (Kadcyla, T-DM1, PD-0332991 and T-DM1)

nadofaragene firadenovec (Adstiladrin, rAd-IFNα/Syn3, nadofaragene firadenovec-vncg)

89Zr-Df-IAB22M2C (89Zr-Df-IAB22M2C)

Zilovertamab vedotin (Zilovertamab vedotin)

AVL (AAV8hAAT, AAV8hAAT(AVL))

disitamab vedotin (Disitamab Vedotin, RC48, Disitamab Vedotin Combined With Sintilimab)

Anti-CD19 CAR T Cells Preparation (Anti-CD19 CAR T Cells Preparation)

함께 비교하는 진짜 ADC · Antibody · CGT 데이터

추천 비교

빠른 검색 · 이슈 태그

실시간 이슈 · 검색

anti-MESO CAR-T cells (anti-MESO CAR-T cells)

Anti-CD33 CAR T-cells (Anti-CD33 CAR T-cells)

disitamab vedotin (Disitamab Vedotin, RC48, RC48 Combined With Tislelizumab)

Topical infliximab (Topical infliximab)

CDK4/6 inhibitor+AI or fulvestrant (CDK4/6 inhibitor+AI or fulvestrant)

Becotatug Vedotin and Pucotenlimab (Becotatug Vedotin and Pucotenlimab)

MRG003+Pucotenlimab (MRG003+Pucotenlimab)

KYV-101 anti-CD19 CAR-T cell therapy (KYV-101 anti-CD19 CAR-T cell therapy)

PF-08634404 (PF-08634404)

ABBV-399 (ABBV-399)

ASTX660 (ASTX660)

Transplant Conditioning with Mobilization and Alemtuzumab (Transplant Conditioning with Mobilization and Alemtuzumab)

Candonilimab (Candonilimab)

durvalumab (Imfinzi, Datopotamab deruxtecan + Durvalumab)

anti-GPC3 CAR-T (anti-GPC3 CAR-T)

JSKN003 (JSKN003)

Panitumumab-IRDye800 (Panitumumab-IRDye800)

disitamab vedotin (Disitamab Vedotin, RC48, RC48 + Carboplatin)

ado-trastuzumab emtansine (Kadcyla, T-DM1, PD-0332991 and T-DM1)